Overview

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Bortezomib
Dexamethasone
Lenalidomide